Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05964621
Status:
RECRUITING
Last Update Posted:
2023-11-28
First Post:
2023-07-03
Brief Title:
Venous Thromboembolism in Primary Pancreatic Tumour Resection
Sponsor:
University of Thessaly
Organization:
University of Thessaly
Study Overview
Official Title:
Venous Thromboembolism in Patients Undergoing Primary Pancreatic Tumour Resection a Prospective Observational Study
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PaTR-VTE
Brief Summary:
This study will evaluate the development of venous thromboembolism VTE and possible determinants in patients with primary pancreatic cancer undergoing pancreatic cancer resection
Detailed Description:
Cancer associated thrombosis CAT is the second cause of death in oncologic patients after tumour progression itself Patients suffering from malignancies are at increased risk for both venous 4-20 and arterial 2-5 thrombotic events Moreover cancer is one of the most important acquired risk factors for the development of venous thromboembolism VTE
Pancreatic cancer is the fourth most deadly cancer world-widely and has been recognised as the most prothrombotic malignancy with a reported incidence of VTE 8-18 followed by renal and ovarian cancer VTE 56 Although the exact pathophysiological mechanisms are still poorly understood it seems that pancreatic cancer induces a prothrombotic and hypercoagulable state
Aims
To evaluate the predictive value of preoperatively or early postoperatively obtained NLR in patients with primary pancreatic cancer undergoing pancreatic cancer resection for VTE up to the 30rd postoperative day
To evaluate the predictive value of preoperatively or early postoperatively obtained coagulation biomarkersparameters in patients with primary pancreatic cancer undergoing pancreatic cancer resection for VTE up to the 30rd postoperative day
To evaluate the incidence of VTE in patients with primary pancreatic cancer undergoing pancreatic cancer resection
To assess the perioperative coagulation status of patients with primary pancreatic cancer undergoing pancreatic cancer resection
To evaluate any possible determinant or predictive factor for VTE among the coagulation parameters or patients baseline characteristics
Pancreatic cancer is the fourth most deadly cancer world-widely and has been recognised as the most prothrombotic malignancy with a reported incidence of VTE 8-18 followed by renal and ovarian cancer VTE 56 Although the exact pathophysiological mechanisms are still poorly understood it seems that pancreatic cancer induces a prothrombotic and hypercoagulable state
Aims
To evaluate the predictive value of preoperatively or early postoperatively obtained NLR in patients with primary pancreatic cancer undergoing pancreatic cancer resection for VTE up to the 30rd postoperative day
To evaluate the predictive value of preoperatively or early postoperatively obtained coagulation biomarkersparameters in patients with primary pancreatic cancer undergoing pancreatic cancer resection for VTE up to the 30rd postoperative day
To evaluate the incidence of VTE in patients with primary pancreatic cancer undergoing pancreatic cancer resection
To assess the perioperative coagulation status of patients with primary pancreatic cancer undergoing pancreatic cancer resection
To evaluate any possible determinant or predictive factor for VTE among the coagulation parameters or patients baseline characteristics
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None